Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome.

González López-Valcárcel B, Librero J, García-Sempere A, Peña LM, Bauer S, Puig-Junoy J, Oliva J, Peiró S, Sanfélix-Gimeno G.

Heart. 2017 Jul;103(14):1082-1088. doi: 10.1136/heartjnl-2016-310610. Epub 2017 Mar 1.


The Role of Consumer-Controlled Personal Health Management Systems in the Evolution of Employer-Based Health Care Benefits.

Jones SS, Caloyeras J, Mattke S.

Rand Health Q. 2011 Sep 1;1(3):2. eCollection 2011 Fall.


Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.

Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD.

Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630.


Medication Nonadherence: The Role of Cost, Community, and Individual Factors.

Abbass I, Revere L, Mitchell J, Appari A.

Health Serv Res. 2017 Aug;52(4):1511-1533. doi: 10.1111/1475-6773.12547. Epub 2016 Aug 25.


A renewed Medication Adherence Alliance call to action: harnessing momentum to address medication nonadherence in the United States.

Zullig LL, Granger BB, Bosworth HB.

Patient Prefer Adherence. 2016 Jul 7;10:1189-95. doi: 10.2147/PPA.S100844. eCollection 2016.


Improving medication adherence among kidney transplant recipients: Findings from other industries, patient engagement, and behavioral economics-A scoping review.

Oberlin SR, Parente ST, Pruett TL.

SAGE Open Med. 2016 Jan 21;4:2050312115625026. doi: 10.1177/2050312115625026. eCollection 2016. Review.


Value-Based Benefit Design to Improve Medication Adherence for Employees with Anxiety or Depression.

Reid KJ, Aguilar KM, Thompson E, Miller RM.

Am Health Drug Benefits. 2015 Jul-Aug;8(5):263-71.


The Impact of a Tiered Network on Hospital Choice.

Frank MB, Hsu J, Landrum MB, Chernew ME.

Health Serv Res. 2015 Oct;50(5):1628-48. doi: 10.1111/1475-6773.12291. Epub 2015 Mar 9.


Impact of medicare part D plan features on use of generic drugs.

Tang Y, Gellad WF, Men A, Donohue JM.

Med Care. 2014 Jun;52(6):541-8. doi: 10.1097/MLR.0000000000000142.


Evaluation of the diabetes health plan to improve diabetes care and prevention.

Duru OK, Mangione CM, Chan C, Keckhafer A, Kimbro L, Kirvan KA, Turk N, Luchs R, Li J, Ettner S.

Prev Chronic Dis. 2013;10:E16. doi: 10.5888/pcd10.120150.


Choosing wisely: low-value services, utilization, and patient cost sharing.

Volpp KG, Loewenstein G, Asch DA.

JAMA. 2012 Oct 24;308(16):1635-6. doi: 10.1001/jama.2012.13616. No abstract available.


Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes.

Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS.

Value Health. 2012 May;15(3):404-11. doi: 10.1016/j.jval.2012.01.008. Epub 2012 Apr 10.


The prevalence and cost of unapproved uses of top-selling orphan drugs.

Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J.

PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21.


Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.

Riley GF, Warren JL, Harlan LC, Blackwell SA.

Medicare Medicaid Res Rev. 2011 Dec 13;1(4). doi: 10.5600/mmrr.001.04.a04.


Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

Curtis JR, Yun H, Matthews R, Saag KG, Delzell E.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):1054-60. doi: 10.1002/acr.21638.


Value-based insurance design: more health at any price.

Fendrick AM, Martin JJ, Weiss AE.

Health Serv Res. 2012 Feb;47(1 Pt 2):404-13. doi: 10.1111/j.1475-6773.2011.01358.x. Epub 2011 Dec 8.


Medication adherence: a call for action.

Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, Daniel JG, Ekman I, Ho M, Johnson M, Kimmel SE, Liu LZ, Musaus J, Shrank WH, Whalley Buono E, Weiss K, Granger CB.

Am Heart J. 2011 Sep;162(3):412-24. doi: 10.1016/j.ahj.2011.06.007. Review.


Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.

Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S.

PLoS Med. 2011 Aug;8(8):e1001075. doi: 10.1371/journal.pmed.1001075. Epub 2011 Aug 16. Erratum in: PLoS Med. 2014 Aug;11(8):e1001716.

Supplemental Content

Support Center